Zentalis Pharmaceuticals Grants Stock Options to New Employees Under Nasdaq Rule
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Image: Benzinga
Zentalis Pharmaceuticals, Inc. has granted non-qualified stock options to purchase 191,000 shares to two new employees as part of its 2022 Employment Inducement Incentive Award Plan. The options, priced at $3.98 per share, vest over four years and comply with Nasdaq Listing Rule 5635(c)(4).
- 01Zentalis Pharmaceuticals granted 191,000 stock options to two new employees.
- 02The options were issued under the 2022 Employment Inducement Incentive Award Plan.
- 03Each option has an exercise price of $3.98, equal to the closing stock price on the grant date.
- 04The options have a 10-year term and vest over four years.
- 05Vesting requires continued employment with Zentalis on each vesting date.
Advertisement
In-Article Ad
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a company focused on developing innovative treatments for cancer, announced the granting of non-qualified stock options to two newly hired employees on June 1, 2026. A total of 191,000 shares of the company's common stock were allocated under the 2022 Employment Inducement Incentive Award Plan, which is intended for individuals not previously employed by Zentalis. The stock options have an exercise price set at $3.98 per share, matching the closing price on the Nasdaq Global Market on the grant date. These options come with a 10-year term and will vest over a period of four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments over the subsequent three years. This structure is designed to incentivize the new hires to remain with the company throughout the vesting period.
Advertisement
In-Article Ad
Advertisement
In-Article Ad
Reader Poll
What do you think about stock options as an employee incentive?
Connecting to poll...
Read the original article
Visit the source for the complete story.